Skandinaviska Enskilda Banken Ab (Publ) Immunovant, Inc. Transaction History
Skandinaviska Enskilda Banken Ab (Publ)
- $19.9 Billion
- Q1 2025
A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Immunovant, Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 35,316 shares of IMVT stock, worth $971,543. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,316
Previous 35,316
-0.0%
Holding current value
$971,543
Previous $971,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding IMVT
# of Institutions
226Shares Held
78.4MCall Options Held
1.5MPut Options Held
1.55M-
Deep Track Capital, LP Greenwich, CT9.5MShares$261 Million9.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.94MShares$191 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.89MShares$162 Million0.07% of portfolio
-
Baker Bros. Advisors LP New York, NY5.46MShares$150 Million1.79% of portfolio
-
Black Rock Inc. New York, NY4.92MShares$135 Million0.0% of portfolio
About Immunovant, Inc.
- Ticker IMVT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 129,077,000
- Market Cap $3.55B
- Description
- Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...